APA (7th ed.) Citation

V, W., C, M., A, B., G, D., JB, T., L, K., . . . E, M. (2022). Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillator Therapy in Patients With Tetralogy of Fallot. Journal of the American College of Cardiology, 80(17), 1701. https://doi.org/10.1016/j.jacc.2022.08.761

Chicago Style (17th ed.) Citation

V, Waldmann, et al. "Subcutaneous Vs Transvenous Implantable Cardioverter-Defibrillator Therapy in Patients With Tetralogy of Fallot." Journal of the American College of Cardiology 80, no. 17 (2022): 1701. https://doi.org/10.1016/j.jacc.2022.08.761.

MLA (9th ed.) Citation

V, Waldmann, et al. "Subcutaneous Vs Transvenous Implantable Cardioverter-Defibrillator Therapy in Patients With Tetralogy of Fallot." Journal of the American College of Cardiology, vol. 80, no. 17, 2022, p. 1701, https://doi.org/10.1016/j.jacc.2022.08.761.